Pfiz­er bets $1B cash on the orig­i­nal pro­tein de­graders as tech­nol­o­gy nears prime time

As one of the largest multi­na­tion­al cor­po­ra­tions in the world, Pfiz­er has its ten­drils in every­thing. The Big Phar­ma has po­ten­tial­ly hun­dreds of bil­lions of dol­lars to play with, and when it de­cides to go big, it can go as big as it wants.

And did Pfiz­er ever on Thurs­day.

Re­turn­ing to one of its part­ners in pro­tein degra­da­tion, Pfiz­er is team­ing up again with Arv­inas to ad­vance and vast­ly ex­pand a pro­gram for breast can­cer. As part of the deal, Pfiz­er is hand­ing over $1 bil­lion im­me­di­ate­ly — $650 mil­lion in up­front cash and $350 mil­lion in an eq­ui­ty in­vest­ment — and promis­ing up to an­oth­er $1.4 bil­lion in reg­u­la­to­ry and com­mer­cial mile­stones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER